Alcon Stock Rises in Switzerland Following Confirmation of Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Source: WSJ
Sales Growth: Alcon reported an acceleration in third-quarter sales growth, which positively impacted its share price in Switzerland.
Annual Outlook: The company confirmed its annual outlook, providing reassurance after two previous guidance cuts earlier in the year.
Share Performance: Shares of Alcon rose by 6.3% during European morning trading, although they remain down 15% since the beginning of the year.
Market Reaction: The positive sales report and outlook led to a favorable market reaction, indicating investor confidence despite earlier challenges.
Analyst Views on ALC
Wall Street analysts forecast ALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALC is 91.11 USD with a low forecast of 75.18 USD and a high forecast of 112.77 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
6 Buy
4 Hold
1 Sell
Moderate Buy
Current: 81.020
Low
75.18
Averages
91.11
High
112.77
Current: 81.020
Low
75.18
Averages
91.11
High
112.77
About ALC
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








